Abstract
This study aimed to detect the expression of miR-373-3p and CCND2 in gemcitabine-resistance pancreatic carcinoma (PC) cells, investigate the relationship between miR-373-3p and CCND2, and explore their effects on PC propagation, migration, invasion and apoptosis. R software was applied for analyzing differentially expressed genes (DEGs) in cell samples. The potential biological pathway was determined by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, based on R software. The gemcitabine-resistance PC cells were screened out using MTT assay, and they were applied in the next experiments. MiR-373-3p and CCND2 expression in GEM-PANC-1 cells were measured by qRT-PCR. After transfection, the expression of CCND2 protein was examined via western blot assay. Cells viability and apoptosis were confirmed by MTT proliferation assay and Flow cytometry, whereas cells migration and invasion were analyzed by transwell assay. The targeting relationship between miR-373-3p and CCND2 was identified by dual-luciferase reporter assay. MiR-373-3p was found to be low expressed in GEM-PANC-1 cells while CCND2 was highly expressed in GEM-PANC-1 cells. MiR-373-3p negatively regulated CCND2 expression through KEGG_Cell_Cycle_Signaling_Pa...Continue Reading
References
Jul 13, 2005·Cancer Letters·Ji Kon RyuChung Yong Kim
Mar 28, 2006·Cell·P Mathijs VoorhoeveReuven Agami
Jan 15, 2008·Nature Cell Biology·Qihong HuangReuven Agami
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Assia L AngelovaZahari Raykov
Jun 25, 2009·International Journal of Cancer. Journal International Du Cancer·Thomas GreitherHelge Taubert
Apr 8, 2010·Current Cancer Drug Targets·Asfar S AzmiRamzi M Mohammad
Apr 27, 2010·PloS One·Qingchuan DongHe Wang
Feb 25, 2011·Annals of Surgical Oncology·Kenoki OhuchidaMasao Tanaka
Dec 3, 2011·Cell Cycle·Sean VanceMeredith A Morgan
Nov 8, 2012·PloS One·Vikas YadavNeeru Saini
Jun 27, 2013·British Journal of Cancer·Y IwagamiY Doki
Aug 1, 2013·International Journal of Oncology·Hiroaki NaganoYuichiro Doki
Oct 1, 2013·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Daisuke TakiuchiYuichiro Doki
Nov 13, 2013·Cellular Signalling·Shin HamadaTooru Shimosegawa
Nov 15, 2013·Biomedical Journal·Alexandra Drakaki, Dimitrios Iliopoulos
Jan 9, 2014·International Journal of Oncology·Naotake FunamizuKatsuhiko Yanaga
Apr 22, 2014·Annals of Surgical Oncology·Kohei NakataMasao Tanaka
Aug 26, 2014·Oncotarget·Jianwei XuYupei Zhao
Feb 2, 2015·Oncotarget·Jia MaZhiwei Wang
Apr 8, 2015·The Journal of Surgical Research·Paul A TosteTimothy R Donahue
May 21, 2015·Journal of Translational Medicine·Furong WeiJunfu Wang
Jan 20, 2016·Molecular Medicine Reports·Xiaomei MoFenghai Liu
Dec 13, 2016·Cancer Letters·Prince Saforo AmponsahIngrid Herr
Feb 16, 2017·Scientific Reports·Manabu MikamoriYuichiro Doki
May 26, 2017·Cancer Letters·Amit Kumar ChaudharyRam I Mahato
Aug 2, 2017·Cancer Biomarkers : Section a of Disease Markers·Yongqiang HuaZhiqiang Meng
Sep 10, 2017·Cancer Chemotherapy and Pharmacology·Azam RajabpourLadan Teimoori-Toolabi
Citations
Nov 16, 2019·Bioscience Reports·Wen-Cui LiJuan-Juan Zhang
Nov 27, 2019·Cancer Cell International·Zhuo YeBaoping Qiao
Jul 17, 2020·Journal of Oncology·Cheng DingMenghua Dai
Aug 28, 2020·Frontiers in Oncology·Di WangYi-Qun Che
Oct 28, 2020·Molecular and Cellular Biochemistry·Chong LiLing Chen
Mar 5, 2021·PloS One·Chaoxiong ZhangJialing Yuan
Nov 7, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Zhengjun LinHe Huang
Oct 17, 2020·Journal of Immunology Research·Tao PengLixiang Zhou
Aug 28, 2021·Cells·Lei WangFenge Li
Nov 2, 2020·Experimental and Molecular Pathology·Lei LiWei-Wei Zhu
Nov 10, 2021·Future Oncology·Mei-Qian WangSen-Lin Zhu
Nov 29, 2021·Chinese Medical Journal·Xiangyu ChuYinmo Yang
Jan 6, 2022·Bioengineered·Hongbin LiJun Yin